DT&CRO Co (XKRX:383930) Debt-to-Asset : 0.24 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is DT&CRO Co Debt-to-Asset?

DT&CRO Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩5,399 Mil. DT&CRO Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩12,259 Mil. DT&CRO Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₩73,140 Mil. DT&CRO Co's debt to asset for the quarter that ended in Mar. 2024 was 0.24.

DT&CRO Co Debt-to-Asset Historical Data

The historical data trend for DT&CRO Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DT&CRO Co Debt-to-Asset Chart

DT&CRO Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.17

0.15

0.08

0.27

DT&CRO Co Quarterly Data
	Jun21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial					0.12	0.19	0.20	0.27	0.24

Competitive Comparison of DT&CRO Co's Debt-to-Asset

For the Biotechnology subindustry, DT&CRO Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DT&CRO Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DT&CRO Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where DT&CRO Co's Debt-to-Asset falls into.

DT&CRO Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

DT&CRO Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3577.288	+	12303.275)	/	59847.891
	=	0.27

DT&CRO Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5399.476	+	12258.617)	/	73140.467
	=	0.24

DT&CRO Co (XKRX:383930) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

DT&CRO Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of DT&CRO Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

DT&CRO Co (XKRX:383930) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DT&CRO Co Ltd (XKRX:383930) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

28, Baengnyeong-ro 20beon-gil, 2nd, 3rd, 4th floor, Na-dong, Cheoin-gu, Gyeonggi-do (Yubang-dong), Yongin-si, KOR, 17042

Website

http://www.dtncro.com

DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.

DT&CRO Co (XKRX:383930) Headlines

No Headlines